ArticleCancer biology & therapy2021

Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.

Kate Crawford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.